Nachrichten zur Pharming Group N.V. Aktie

Original-Research: Pharming Group NV (von First Berlin Equity Research GmbH):...

^ Original-Research: Pharming Group NV - from First Berlin Equity Research GmbH 29.10.2024 / 14:51 CET/CEST Dissemination of a Research,…

Original-Research: Pharming Group NV (von First Berlin Equity Research GmbH):...

^Original-Research: Pharming Group NV - from First Berlin Equity ResearchGmbH29.10.2024 / 14:51 CET/CESTDissemination of a Research, transmitted by EQS News…

Pharming Group to report third quarter 2024 financial results on October 24

Leiden, the Netherlands, October 10, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary…

Pharming Group to participate in September investor conferences

Leiden, the Netherlands, September 4, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate…

Original-Research: Pharming Group NV (von First Berlin Equity Research GmbH):...

^Original-Research: Pharming Group NV - from First Berlin Equity ResearchGmbH26.08.2024 / 15:55 CET/CESTDissemination of a Research, transmitted by EQS News…

Original-Research: Pharming Group NV (von First Berlin Equity Research GmbH):...

^ Original-Research: Pharming Group NV - from First Berlin Equity Research GmbH 26.08.2024 / 15:55 CET/CEST Dissemination of a Research,…

Pharming Group reports second quarter and first half 2024 financial results and provides business update

Leiden, the Netherlands, August 1, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) presents its preliminary…

Pharming Group to report second quarter and first half 2024 financial results on August 1

Leiden, the Netherlands, July 18, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary…

Pharming Group N.V. 2024 Q1 - Results - Earnings Call Presentation

…

Pharming Group N.V. (PHAR) Q1 2024 Earnings Call Transcript

…

Pharming Group to report first quarter 2024 financial results on May 8

Leiden, the Netherlands, April 24, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary…

Pharming Group (PHAR) Surges 7.2%: Is This an Indication of Further Gains?

Pharming Group (PHAR) saw its shares surge in the last session with trading volume being higher than average. The latest…

Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025

NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY…

Pharming Group announces the placement of €100 million convertible bonds due 2029

NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY…

Pharming Group announces the 2024 Annual General Meeting of Shareholders

Leiden, The Netherlands, April 4, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces…

Pharming Group announces the filing of its 2023 Annual Report and Form 20-F

Leiden, The Netherlands, April 4, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces…

Pharming Group N.V. (PHAR) Q4 2023 Earnings Call Transcript

…

Pharming Group N.V. 2023 Q4 - Results - Earnings Call Presentation

…

Pharming Group reports fourth quarter and full year 2023 financial results

Leiden, The Netherlands, March 14, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) presents…

Pharming Group to report fourth quarter and full year 2023 financial results on March 14

Leiden, The Netherlands, February 29, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary…

Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update

Expect 10% growth in RUCONEST® revenue, significantly exceeding prior guidance…

Pharming Group provides updates on EMA regulatory review of leniolisib MAA and plans to file for UK regulatory approval

Leiden, The Netherlands, November 10, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that it…

Pharming Group announces presentations at International Primary Immunodeficiencies Congress and the American College of Allergy, Asthma & Immunology Annual Scientific Meeting

Leiden, The Netherlands, November 7, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces 14 poster…

Pharming Group to participate in November investor conferences

Leiden, The Netherlands, November 1, 2023: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate…

Pharming Group N.V. (PHAR) Q3 2023 Earnings Call Transcript

…

Pharming Group N.V. 2023 Q3 - Results - Earnings Call Presentation

…

Pharming Group reports third quarter 2023 financial results

Pharming Group reports third quarter 2023 financial results…

Pharming Group to report third quarter 2023 financial results on October 26

Leiden, The Netherlands, October 12, 2023: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary…

Pharming Group reports on results of the 2023 Extraordinary General Meeting of Shareholders

Leiden, The Netherlands, September 25, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM/Nasdaq: PHAR) announces today that the…

Form 6-K Pharming Group N.V. For: Aug 14

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 6-K Pharming Group N.V. For: Aug 09

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Original-Research: Pharming Group NV (von First Berlin Equity Research GmbH):...

^ Original-Research: Pharming Group NV - von First Berlin Equity Research GmbH Einstufung von First Berlin Equity Research…

Pharming Group N.V. reports Q2 results

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 6-K Pharming Group N.V. For: Jul 18

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Original-Research: Pharming (von First Berlin Equity Research GmbH): Buy

^ Original-Research: Pharming - von First Berlin Equity Research GmbH Einstufung von First Berlin Equity Research GmbH zu…

Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the Board

LEIDEN, The Netherlands, July 18, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces…

Pharming Group to report second quarter and first half 2023 financial results on August 3

LEIDEN, The Netherlands, July 13, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report…

Form 6-K Pharming Group N.V. For: Jun 01

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 6-K Pharming Group N.V. For: May 17

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Pharming Group reports on results of the 2023 Annual General ...

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

Pharming GAAP EPS of -$0.01, revenue of $42.54M

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Pharming Group N.V. GAAP EPS of $0.02, revenue of $42.5M misses by $6M

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Pharming Group reports financial results for the first quarter of 2023

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

Pharming Group reports financial results for the first quarter of 2023

FDA approval and commercial launch of Joenja® (leniolisib) in the U.S. Joenja® launch off to strong start with 23 U.S.…

Strength Seen in Pharming Group N.V. Sponsored ADR (PHAR): Can Its 5.2% Jump Turn into More Strength?

Pharming Group N.V. Sponsored ADR (PHAR) witnessed a jump in share price last session on above-average trading volume. The latest…

Notice of First Quarter 2023 Results

LEIDEN, Netherlands, April 19, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM) (Nasdaq: PHAR) confirms it will announce…

Form 6-K Pharming Group N.V. For: Apr 11

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 6-K Pharming Group N.V. For: Apr 05

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Pharming Group convenes the Annual General Meeting of Shareholders 2023

LEIDEN, Netherlands, April 5, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM) (Nasdaq: PHAR) announces that…

Pharming Group announces the filing of its 2022 Annual Report and Form 20-F

LEIDEN, The Netherlands, April 5, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") ( Euronext: PHARM / Nasdaq:…